{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:45:52Z","timestamp":1768621552489,"version":"3.49.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Chugai Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.dmpk.2016.03.003","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T06:49:41Z","timestamp":1458802181000},"page":"276-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers"],"prefix":"10.1016","volume":"31","author":[{"given":"Kenta","family":"Haraya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2016.03.003_bib1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/dmd.111.040923","article-title":"Prediction of in\u00a0vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver","volume":"40","author":"Sanoh","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1124\/dmd.111.042309","article-title":"Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs","volume":"40","author":"Zanelli","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib3","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in\u00a0vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib4","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s11095-010-0218-3","article-title":"Prediction of human metabolic clearance from in\u00a0vitro systems: retrospective analysis and prospective view","volume":"27","author":"Hallifax","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.dmpk.2016.03.003_bib5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/00498254.2012.733831","article-title":"A\u00a0new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data","volume":"43","author":"Ogawa","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2016.03.003_bib6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2133\/dmpk.DMPK-09-RG-038","article-title":"Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans","volume":"25","author":"Kato","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.03.003_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2133\/dmpk.25.243","article-title":"Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature","volume":"25","author":"Ito","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.03.003_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2133\/dmpk.DMPK-11-RG-078","article-title":"Inter-individual variability of in\u00a0vivo CYP2D6 activity in different genotypes","volume":"27","author":"Chiba","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.03.003_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/14622416.9.5.625","article-title":"Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms","volume":"9","author":"Gunes","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.dmpk.2016.03.003_bib12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2174\/138920008786049302","article-title":"Clinical pharmacogenetics and potential application in personalized medicine","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmpk.2016.03.003_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmpk.2016.03.003_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00228-007-0438-6","article-title":"Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes","volume":"64","author":"Djordjevic","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","article-title":"Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype\u2013phenotype relationship in Swedes and Koreans","volume":"63","author":"Ghotbi","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/pgs.09.22","article-title":"Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population","volume":"10","author":"Gunes","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.dmpk.2016.03.003_bib17","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00228-006-0205-0","article-title":"Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls","volume":"62","author":"Petersen","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00007691-200008000-00008","article-title":"Evaluation of caffeine as an in\u00a0vivo probe for CYP1A2 using measurements in plasma, saliva, and urine","volume":"22","author":"Carrillo","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2016.03.003_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00228-007-0389-y","article-title":"Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine","volume":"64","author":"Backman","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/bdd.711","article-title":"Prediction of human blood-to-plasma drug concentration ratio","volume":"31","author":"Uchimura","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2125.1998.00679.x","article-title":"Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes","volume":"45","author":"Eagling","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2125.1990.tb03686.x","article-title":"Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man","volume":"29","author":"Sesardic","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2125.1987.tb03003.x","article-title":"Accumulation of caffeine in healthy volunteers treated with furafylline","volume":"23","author":"Tarrus","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib24","first-page":"89","article-title":"CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans","volume":"54","author":"Boobis","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.dmpk.2016.03.003_bib25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2125.2003.02028.x","article-title":"Tizanidine is mainly metabolized by cytochrome p450 1A2 in\u00a0vitro","volume":"57","author":"Granfors","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199204000-00004","article-title":"Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1","volume":"2","author":"Gu","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.dmpk.2016.03.003_bib27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0090-9556(24)15170-7","article-title":"Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans","volume":"28","author":"Wang","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jps.22255","article-title":"Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection","volume":"100","author":"Kawakami","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmpk.2016.03.003_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.2042-7158.1986.tb04540.x","article-title":"Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model","volume":"38","author":"Roberts","year":"1986","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib30","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/dmd.31.5.580","article-title":"Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in\u00a0vivo and in\u00a0vitro","volume":"31","author":"Naritomi","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.1840090222","article-title":"The effect of age upon liver volume and apparent liver blood flow in healthy man","volume":"9","author":"Wynne","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.dmpk.2016.03.003_bib32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF00609624","article-title":"Pharmacokinetic and pharmacodynamic studies of tienilic acid in healthy volunteers","volume":"22","author":"Kerremans","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1067\/mcp.2000.103860","article-title":"In\u00a0vivo effects of interleukin-10 on human cytochrome P450 activity","volume":"67","author":"Gorski","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF00542550","article-title":"Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants","volume":"22","author":"Pirttiaho","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2125.1985.tb02641.x","article-title":"The effects of age and smoking on the plasma protein binding of lignocaine and diazepam","volume":"19","author":"Davis","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","article-title":"Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations","volume":"84","author":"Myrand","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0076-6879(96)72014-1","article-title":"Chlorzoxazone: an in\u00a0vitro and in\u00a0vivo substrate probe for liver CYP2E1","volume":"272","author":"Lucas","year":"1996","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib38","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/tx00018a012","article-title":"Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1","volume":"3","author":"Peter","year":"1990","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/bdd.2510150706","article-title":"Variability in the disposition of chlorzoxazone","volume":"15","author":"de Vries","year":"1994","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00008571-199906000-00013","article-title":"Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans","volume":"9","author":"Lucas","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.dmpk.2016.03.003_bib41","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0022-3565(25)25761-5","article-title":"Physiological disposition and metabolic fate of chlorzoxazone (paraflex) in man","volume":"128","author":"Conney","year":"1960","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0091270005282635","article-title":"Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe","volume":"46","author":"Park","year":"2006","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib43","first-page":"160","article-title":"A\u00a0study on the pharmacokinetics of chlorzoxazone in healthy Thai volunteers","volume":"90","author":"Prompila","year":"2007","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.dmpk.2016.03.003_bib44","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0006-2952(94)90524-X","article-title":"Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics","volume":"47","author":"Girre","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib45","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/jps.2600720905","article-title":"Pharmacokinetics of chlorzoxazone in humans","volume":"72","author":"Desiraju","year":"1983","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmpk.2016.03.003_bib46","doi-asserted-by":"crossref","first-page":"e40883","DOI":"10.1371\/journal.pone.0040883","article-title":"Systematic functional characterization of cytochrome P450 2E1 promoter variants in the Chinese Han population","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.dmpk.2016.03.003_bib47","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s13277-013-0762-7","article-title":"CYP2E1 T7632A and 9-bp insertion polymorphisms and colorectal cancer risk: a meta-analysis based on 4,592 cases and 5,918 controls","volume":"34","author":"Qian","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00498250600683197","article-title":"Prediction of in\u00a0vivo drug clearance from in\u00a0vitro data. I: impact of inter-individual variability","volume":"36","author":"Howgate","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2016.03.003_bib49","first-page":"168","article-title":"Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes","volume":"25","author":"Yamazaki","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/abbi.1996.0294","article-title":"Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity","volume":"331","author":"Pearce","year":"1996","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.dmpk.2016.03.003_bib51","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/03602530903286476","article-title":"Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2","volume":"42","author":"Zhou","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmpk.2016.03.003_bib52","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1210\/mend-3-9-1399","article-title":"Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression","volume":"3","author":"Ikeya","year":"1989","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00008571-199310000-00003","article-title":"Expression of CYP1A1 and CYP1A2 genes in human liver","volume":"3","author":"Schweikl","year":"1993","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.dmpk.2016.03.003_bib54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1124\/mol.64.3.659","article-title":"Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1","volume":"64","author":"Aklillu","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2133\/dmpk.20.24","article-title":"Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population","volume":"20","author":"Soyama","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.03.003_bib56","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/carcin\/17.4.793","article-title":"Effects of dietary broccoli on human in\u00a0vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism","volume":"17","author":"Kall","year":"1996","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.dmpk.2016.03.003_bib57","first-page":"6154","article-title":"Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans","volume":"54","author":"Sinha","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.dmpk.2016.03.003_bib58","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0009-9236(98)90105-9","article-title":"Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping","volume":"63","author":"Kashuba","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2133\/dmpk.DMPK-13-RG-137","article-title":"Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans","volume":"29","author":"Chiba","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.03.003_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.1989.23","article-title":"Effect of quinolones on caffeine disposition","volume":"45","author":"Carbo","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib61","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1124\/dmd.108.020479","article-title":"Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds","volume":"36","author":"Obach","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib62","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-9556(24)15277-4","article-title":"A\u00a0controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state","volume":"27","author":"Shellenberger","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib63","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/dmd.30.8.892","article-title":"Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method","volume":"30","author":"Shibata","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib64","first-page":"629","article-title":"Influence of phenacetin and its metabolites on renal function","volume":"31","author":"Mineshita","year":"1989","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"10.1016\/j.dmpk.2016.03.003_bib65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.1989.tb05383.x","article-title":"Lack of effect of terfenadine on theophylline pharmacokinetics and metabolism in normal subjects","volume":"27","author":"Brion","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib66","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1399-6576.1985.tb02305.x","article-title":"Serum concentrations and urinary excretion of lidocaine and its two desethylated metabolites after spinal anaesthesia using lidocaine or lidocaine with phenylephrine","volume":"29","author":"Lindberg","year":"1985","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.dmpk.2016.03.003_bib67","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/009127009903900308","article-title":"Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine","volume":"39","author":"Amchin","year":"1999","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2710.2008.00976.x","article-title":"Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models","volume":"34","author":"Seng","year":"2009","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib69","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1128\/AAC.33.4.474","article-title":"Interaction between oral ciprofloxacin and caffeine in normal volunteers","volume":"33","author":"Healy","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmpk.2016.03.003_bib70","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/00365519609088615","article-title":"Assessment of dimethylxanthine formation from caffeine in healthy adults: comparison between plasma and saliva concentrations and urinary excretion of metabolites","volume":"56","author":"Rodopoulos","year":"1996","journal-title":"Scand J Clin Lab Investig"},{"key":"10.1016\/j.dmpk.2016.03.003_bib71","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00228-003-0631-1","article-title":"Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers","volume":"59","author":"Gelal","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib72","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2125.2005.02467.x","article-title":"Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics","volume":"60","author":"Culm-Merdek","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib73","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clinthera.2007.04.012","article-title":"Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects","volume":"29","author":"Henney","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2125.2006.02653.x","article-title":"Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects","volume":"62","author":"Backman","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib75","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2003.12.005","article-title":"Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction","volume":"75","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00228-006-0127-x","article-title":"Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine","volume":"62","author":"Backman","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib77","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clpt.2005.06.009","article-title":"Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2","volume":"78","author":"Granfors","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib78","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.clpt.2004.08.018","article-title":"Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism","volume":"76","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib79","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.clinthera.2008.12.014","article-title":"Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects","volume":"30","author":"Henney","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib80","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00228-007-0456-4","article-title":"Celecoxib is a CYP1A2 inhibitor in\u00a0vitro but not in\u00a0vivo","volume":"64","author":"Karjalainen","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib81","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00007691-199406000-00004","article-title":"Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers","volume":"16","author":"Xiaodong","year":"1994","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2016.03.003_bib82","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00007691-199610000-00011","article-title":"The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate","volume":"18","author":"Bartoli","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2016.03.003_bib83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00007691-199808000-00002","article-title":"Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects","volume":"20","author":"Dong","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2016.03.003_bib84","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1128\/AAC.40.8.1866","article-title":"Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers","volume":"40","author":"Gillum","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmpk.2016.03.003_bib85","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0149-2918(00)83047-7","article-title":"Effect of citalopram on plasma levels of oral theophylline","volume":"22","author":"Moller","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/1099-081X(199912)20:9<417::AID-BDD205>3.0.CO;2-W","article-title":"Bioequivalence of immediate-release theophylline capsules","volume":"20","author":"Meyer","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib87","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/j.1875-9114.1990.tb02595.x","article-title":"The influence of enteral feedings on sustained-release theophylline absorption","volume":"10","author":"Plezia","year":"1990","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.dmpk.2016.03.003_bib88","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/bdd.2510110209","article-title":"Bioavailability of a new sustained-release theophylline capsule in fasted and non-fasted healthy subjects: single and multiple dosing studies","volume":"11","author":"West","year":"1990","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmpk.2016.03.003_bib89","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00007691-198909000-00004","article-title":"Effect of an enteral nutrient formula on sustained-release theophylline absorption","volume":"11","author":"Bhargava","year":"1989","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2016.03.003_bib90","first-page":"222","article-title":"Effect of drug intake prior to or after meals on serum theophylline concentrations: single-dose studies with Euphylong","volume":"25","author":"Schulz","year":"1987","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib91","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00007691-198512000-00011","article-title":"Cimetidine\u2013theophylline interaction: effects of age and cimetidine dose","volume":"7","author":"Cohen","year":"1985","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2016.03.003_bib92","first-page":"415","article-title":"Fluvoxamine\u2013theophylline interaction: gap between in\u00a0vitro and in\u00a0vivo inhibition constants toward cytochrome P4501A2","volume":"70","author":"Yao","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib93","first-page":"732","article-title":"Influence of food on the bioavailability of theophylline from a sustained-released theophylline preparation","volume":"41","author":"Lohmann","year":"1991","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.dmpk.2016.03.003_bib94","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/00007691-198512000-00014","article-title":"Comparison of high pressure liquid chromatography and fluorescence polarization immunoassay methods in a theophylline pharmacokinetic study","volume":"7","author":"Lalonde","year":"1985","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2016.03.003_bib95","first-page":"309","article-title":"Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis","volume":"79","author":"Tonsuwannont","year":"1996","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.dmpk.2016.03.003_bib96","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/cpt1979266701","article-title":"Rectal bioavailability of lidocaine in man: partial avoidance of \u201cfirst-pass\u201d metabolism","volume":"26","author":"de Boer","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.03.003_bib97","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1742-7843.2006.pto_482.x","article-title":"Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine","volume":"99","author":"Isohanni","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib98","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-0773.1999.tb00890.x","article-title":"Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine","volume":"84","author":"Isohanni","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2125.1979.tb05904.x","article-title":"Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients","volume":"8","author":"Perucca","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.03.003_bib100","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2125.1985.tb02686.x","article-title":"The impairment of lignocaine clearance by propranolol \u2013 major contribution from enzyme inhibition","volume":"19","author":"Bax","year":"1985","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436716300064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436716300064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:53:10Z","timestamp":1761162790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436716300064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1347436716300064"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.03.003","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}